Brendan D. Curti

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 11 papers. Top paper: “DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing): A phase III trial—ECOG-ACRIN EA6134.”.

DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing): A phase III trial—ECOG-ACRIN EA6134.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.36_suppl.356154

N/A

5.7DataRank · unranked

111 citations

Sandra J. Lee, Bartosz Chmielowski, Antoni Ribas, Ahmad A. Tarhini, Thach‐Giao Truong +9 more

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134

Journal of Clinical Oncology(2022)10.1200/jco.22.01763

N/A

5.4DataRank · unranked

446 citations

Sandra J. Lee, Bartosz Chmielowski, Ahmad A. Tarhini, Gary I. Cohen, Thach‐Giao Truong +31 more

Randomized phase II study of stereotactic body radiotherapy and interleukin-2 versus interleukin-2 in patients with metastatic melanoma

Journal for ImmunoTherapy of Cancer(2020)10.1136/jitc-2020-000773

N/A

1.9DataRank · unranked

45 citations

Marka R. Crittenden, Steven K. Seung, Christopher Fountain, Roxanne Payne, Shu‐Ching Chang +6 more

High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma

Frontiers in Oncology(2020)10.3389/fonc.2019.01483

N/A

0.865DataRank · unranked

12 citations

Howard L. Kaufman, Brendan D. Curti, Janice M. Mehnert, Kim Margolin, David F. McDermott +10 more

A phase 1 study of triple‐targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF‐mutated cancers

Cancer(2024)10.1002/cncr.35200

N/A

0.612DataRank · unranked

12 citations

James Moon, Christopher D. Lao, Bartosz Chmielowski, Kari Kendra, Karl D. Lewis +12 more

Early quality of life (QOL) and symptom analysis from the DREAMseq phase III randomized control trial of combination immunotherapy versus targeted therapy in patients (pts) with BRAF-mutant metastatic melanoma (MM) (ECOG-ACRIN EA6134).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.9559

N/A

0.165DataRank · unranked

2 citations

Yue Zheng, Michael B. Atkins, Bartosz Chmielowski, Ahmad A. Tarhini, Thach‐Giao Truong +14 more

HDAC inhibition prevents transgene expression downregulation and loss-of-function in T cell-receptor-transduced T cells

Molecular Therapy — Oncolytics(2021)10.1016/j.omto.2021.01.014

N/A

0DataRank · unranked

10 citations

Gina Scurti, Matthew DeJong, Siao‐Yi Wang, Annika V. Dalheim, Courtney Wagner +13 more

Regulation of human and mouse bystander T cell activation responses by PD-1

JCI Insight(2023)10.1172/jci.insight.173287

N/A

0DataRank · unranked

14 citations

Logan V. Vick, Craig Collins, Cordelia Dunai, Michael K. Sheng, Lam T. Khuat +11 more

Systemic immunostimulation induces glucocorticoid-mediated thymic involution succeeded by rebound hyperplasia which is impaired in aged recipients

Frontiers in Immunology(2024)10.3389/fimmu.2024.1429912

N/A

0DataRank · unranked

7 citations

Lam T. Khuat, Gail D. Sckisel, Logan V. Vick, Christine M. Minnar, Cordelia Dunai +14 more

Full Collection of Personal Narratives

Narrative Inquiry in Bioethics(2022)10.1353/nib.2022.0020

N/A

0DataRank · unranked

0 citations

Joel S. Perlmutter, Brendan D. Curti, Leslie G. Matthews, Leah A. Murray, Ahmet Höke +9 more

Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2021-002371

N/A

0DataRank · unranked

99 citations

Yoshinobu Koguchi, Rom S. Leidner, Annah S. Rolig, Elizabeth R. Sturgill, Zhaoyu Sun +15 more